In MCF-7/DOX, combined treatment upregulated ERα and downregulated LncRNA H19 relative to DOX monotherapy, whereas in MDA-MB-231, it upregulated LncRNA H19 compared with DOX monotherapy.<h4>Conclusion</h4>LIG mitigated DOX-induced resistance through inhibiting autophagy, restoring ERα expression, and downregulating LncRNA H19 in the DOX-resistant BC cell line, thereby presenting a potential therapeutic approach in BC treatment. This evidence concerns the gene H19 and breast cancer.